[HTML][HTML] The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: focus on acute myeloid leukemia
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - cir.nii.ac.jp
抄録< jats: p> Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy.
To treat the disease successfully, new therapeutic strategies are urgently needed. One of …
To treat the disease successfully, new therapeutic strategies are urgently needed. One of …
[PDF][PDF] The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - J. Clin. Med, 2020 - pdfs.semanticscholar.org
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - europepmc.org
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - Journal of clinical medicine, 2020 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
[HTML][HTML] The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - search.proquest.com
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
M Muñoz, R Coveñas - Journal of Clinical Medicine, 2020 - search.ebscohost.com
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - 2020 - preprints.org
Acute myeloid leukemia (AML) is an incurable hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …
[PDF][PDF] The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
M Muñoz, R Coveñas - 2020 - scholar.archive.org
Acute myeloid leukemia (AML) is an incurable hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …
disease successfully, new therapeutic strategies are urgently needed. One of these …